Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pediatric

Familial Patterns in Childhood- & Adult-Onset SLE

Kurt Ullman  |  October 12, 2020

A study examining familial patterns of systemic lupus erythematosus (SLE) found a greater decline in SLE recurrence rate by generation in childhood- than in adult-onset SLE, suggesting adult-onset SLE may be characterized by environmental risk factors.

Filed under:ConditionsPediatric ConditionsSystemic Lupus Erythematosus Tagged with:childhood-onset SLEfamilygeneticPediatricSLEsystemic lupus erythematosus (SLE)

ACR Convergence 2020: From Clinic to Capitol Hill Session Offers Insights into Advocacy, Regulatory Issues

Vanessa Caceres  |  October 2, 2020

Attendees at the ACR Convergence session will learn about key regulatory issues affecting rheumatology and how to add their voices to strengthen the ACR’s advocacy efforts.

Filed under:ACR ConvergenceMeeting Reports Tagged with:ACR Convergence 2020AdvocacyBlair SolowZachary Wallace

RheumPAC Hosts Rep. Kim Schrier, MD, for Legislative Update

From the College  |  October 2, 2020

RheumPAC donors attended a virtual legislative update and Q&A with former pediatrician Rep. Kim Schrier, MD (D-Wash.), to gain an insider’s view of current healthcare legislation.

Filed under:Legislation & Advocacy Tagged with:Kim SchrierRheumPAC

Changes in ICD-10 for Sjögren’s Syndrome

From the College  |  October 1, 2020

A code change in the ICD-10 classification for Sjögren’s syndrome was approved by the ICD-10 Coordination and Maintenance Committee in July 2019 and becomes effective October 2020.

Filed under:Billing/CodingConditionsOther Rheumatic ConditionsSjögren’s Disease Tagged with:ICD-10ICD-10 code change requestSjogren's

New Classification Criteria Describe Several Hereditary Fevers

Larry Beresford  |  September 21, 2020

Evidence-based classification criteria for rare, hereditary, autoinflammatory fevers have been developed to aid clinicians in better understanding the differences between these rare conditions.

Filed under:Conditions Tagged with:ClassificationClassification CriteriaFamilial Mediterranean feverfeverheredity

Providers & Patients Talk to Legislators about Telehealth, Workforce Shortage

Carina Stanton  |  September 18, 2020

On Sept. 15, rheumatology advocates met virtually with members of Congress to share personal accounts of how telehealth is making a difference during the COVID-19 pandemic and what will help stem a workforce shortage.

Filed under:Legislation & AdvocacyWorkforce Tagged with:Advocates for ArthritisCOVID-19telehealthVirtual Hill Dayworkforce shortage

Ethics Forum: The Ethical Considerations of Prior Authorization

Christina Schutt, DO, FAAP  |  September 17, 2020

The mother of a 15-year-old patient with juvenile idiopathic arthritis/enthesitis-related arthritis (JIA/ERA) called the office in tears. She said she was having an insurance problem. Her son had been a star track athlete when he developed severe back pain. Magnetic resonance imaging showed evidence of severe sacroiliitis. He was started on a tumor necrosis factor…

Filed under:EthicsInsurance Tagged with:EthicsEthics Foruminsuranceprior authorization

Nancy Bates Allen, MD, in the Spotlight

Gretchen Henkel  |  September 11, 2020

Nancy Bates Allen, MD, now professor emeritus, Duke University Medical School, Division of Rheuma­tology and Immunology, Durham, N.C., created a legacy of clinical care, clinical research, advocacy for women and collegial respect during her 42-year career at Duke. David S. Caldwell, MD, FACP, FACR, associate professor of medicine, Duke University School of Medicine, says, “[I’m]…

Filed under:Profiles Tagged with:Dr. Nancy Bates Allen

Billion Photos / shutterstock.com

How to Succeed in a Fellowship & Beyond

Bethany Marston, MD, & Jason Kolfenbach, MD  |  September 11, 2020

For most doctors, fellowship training represents the final two to three years of formal medical education, and recognition of the unique opportunities of this time period can help aspiring rheumatologists get the most out of their fellowship. Fellowship training is inherently different than residency training, with less structured time, smaller teams (often consisting of only…

Filed under:Education & TrainingProfessional Topics Tagged with:Fellows-in-Training

Jury Out on Immunomodulatory Therapy for Kids with Severe COVID-19

Megan Brooks  |  September 1, 2020

NEW YORK (Reuters Health)—Immunomodulatory therapy is not recommended for most children with COVID-19 who typically will have a mild to moderate course of illness, experts advise in a guidance document in the Journal of the Pediatric Infectious Diseases Society.1 For children with severe or critical COVID-19, immunomodulatory agents “may be beneficial,” but the risks and…

Filed under:ConditionsPediatric Conditions Tagged with:ChildrenCOVID-19Pediatric

  • « Previous Page
  • 1
  • …
  • 41
  • 42
  • 43
  • 44
  • 45
  • …
  • 109
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences